ArticlePloS one2026
The prognostic value of thromboelastography MA/R ratio in predicting mortality in acute respiratory failure patients.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thromboelastography (TEG) MA/R ratio reflects coagulation status and thrombus strength. This study evaluated its prognostic value in acute respiratory failure (ARF). A retrospective analysis of 371 ARF patients admitted to the ICU, stratified by MA/R quartiles. Outcomes included 28-day mortality, deep vein thrombosis (DVT), mechanical ventilation duration, and ICU stay. Cox proportional hazards regression model was used to assess hazard ratios, restricted cubic spline was employed to evaluate the nonlinear relationship between MA/R and mortality, and Kaplan-Meier analysis was conducted to compare survival time across different MA/R groups. Patients in the lowest MA/R quartile (Q1) had significantly higher 28-day mortality (59.8% vs. 22.1-28.0% in Q2-Q4; P < 0.001) and elevated inflammatory markers (cytokines, procalcitonin, lactate, creatinine; P < 0.05). DVT incidence, ventilation duration, and ICU stay did not differ between groups. Multivariate analysis identified MA/R as an independent mortality predictor (P < 0.05), with mortality risk sharply increasing below a threshold of 9.7. Kaplan-Meier curves showed shorter survival in Q1 (P < 0.001). The MA/R ratio measured at ICU admission can rapidly identify coagulation dysfunction in patients with acute respiratory failure, with a low MA/R ratio being a strong indicator of poor prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.